![Peter DeMuth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 8 500 $ in data 31/05/2026
Peter DeMuth currently works at Elicio Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. DeMuth also formerly worked at Elicio Therapeutics, Inc. (United States), as Chief Scientific Officer from 2022 to 2023.
Dr. DeMuth received his doctorate degree in 2013 from Massachusetts Institute of Technology and undergraduate degree in 2008 from the University of Maryland.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 09/04/2026 | 743 ( 0% ) | 8 500 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
| Società | Posizione | Fine |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Direttore Tecnico/Scientifico/R&S | 01/06/2023 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elicio Therapeutics, Inc.
 Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
